Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Asterisk, The Current Fiscal Year Ordinary Profit Revised Downward by 82%
6522 Asterisk Inc. 【J-GAAP】
Earnings ReportAsterisk Inc. <6522> [TSE Growth] announced its financial results after the market closed on April 14th (15:30). The consolidated ordinary loss for the cumulative second quarter of the fiscal year ending August 2025 (September 2024 to February 2025) was a reduced loss of 18 million yen (compared to a loss of 121 million yen in the same period last year), reversing from the forecast of a 17 million yen to a loss.
In addition, the full-year consolidated ordinary profit has decreased 82.1%, from the previous forecast of 218 million yen to 39 million yen (compared to a loss of 176 million yen in the previous period).
Based on the first-half performance announced by the company and the full-year plan, our calculation indicates that the consolidated ordinary profit/loss for the March to August period (2H) is expected to turn into a profit of 57 million yen (compared to a loss of 55 million yen in the same period last year).
In the most recent three-month period, from December to February (2Q), the consolidated ordinary profit/loss turned to a profit of 36 million yen (compared to a loss of 30 million yen in the same period last year). The operating profit/loss margin drastically improved from -11.2% in the same period last year to 6.0%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Sep - Feb, 2022 | 869 | -38 | -23 | -12 | -1.8 | ー | Apr 14, 2023 | J-GAAP |
Sep - Feb, 2023 | 658 | -160 | -121 | -197 | -27.8 | ー | Apr 12, 2024 | J-GAAP |
Sep - Feb, 2024 | 875 | -15 | -18 | -23 | -3.2 | ー | Apr 14, 2025 | J-GAAP |
YoY | +33.0% | +90.6% | +85.1% | +88.3% | +88.5% |
First Half Results vs. Previous Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Sep - Feb, 2024 Guidance | 1,160 | 19 | 17 | 2 | 0.3 | 0 | Oct 15, 2024 | J-GAAP |
Sep - Feb, 2024 Results | 875 | -15 | -18 | -23 | -3.2 | 0 | Apr 14, 2025 | J-GAAP |
Revision Rate | -24.6% | - | - | - | - |
Guidance Update
Full Year Update
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Aug, 2025 Prev | 2,719 | 223 | 218 | 99 | 12.7 | 0 | Oct 15, 2024 | J-GAAP |
Aug, 2025 New | 2,200 | 50 | 39 | 15 | 1.9 | 0 | Apr 14, 2025 | J-GAAP |
Revision Rate | -19.1% | -77.6% | -82.1% | -84.8% | -84.9% |
Current Period Guidance
Second Half Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar - Aug, 2024 | 920 | -64 | -55 | -192 | -27.1 | 0 | Oct 15, 2024 | J-GAAP |
Mar - Aug, 2025 Guidance | 1,325 | 65 | 57 | 38 | 4.9 | 0 | Apr 14, 2025 | J-GAAP |
YoY | +44.0% | - | - | - | - |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Aug, 2023 | 1,759 | -192 | -179 | -170 | -24.0 | 0 | Oct 13, 2023 | J-GAAP |
Aug, 2024 | 1,578 | -224 | -176 | -389 | -54.8 | 0 | Oct 15, 2024 | J-GAAP |
Aug, 2025 Guidance | 2,200 | 50 | 39 | 15 | 1.9 | 0 | Apr 14, 2025 | J-GAAP |
YoY | +39.4% | - | - | - | - |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec - Feb, 2023 | 365 | -41 | -30 | -119 | -16.8 | -11.2 | Apr 12, 2024 | J-GAAP |
Mar - May, 2024 | 449 | -78 | -71 | -174 | -24.5 | -17.4 | Jul 12, 2024 | J-GAAP |
Jun - Aug, 2024 | 471 | 14 | 16 | -18 | -2.5 | 3.0 | Oct 15, 2024 | J-GAAP |
Sep - Nov, 2024 | 391 | -44 | -54 | -59 | -8.3 | -11.3 | Jan 10, 2025 | J-GAAP |
Dec - Feb, 2024 | 484 | 29 | 36 | 36 | 5.0 | 6.0 | Apr 14, 2025 | J-GAAP |
YoY | +32.6% | - | - | - | - |
Related Articles
STUDIO ALICE, 6% Decrease in Ordinary Profit for The Current Fiscal Year
COSMOS Pharma, Jun-Feb (Cumulative 3Q) Ordinary Profit Increases by 30%, Dec-Feb Ordinary Profit Increases by 40%
FP Partner, Dec-Feb (1Q) Ordinary Profit Decreases by 42%
DIP, 10% Decrease in Ordinary Profit for The Current Fiscal Year
Totenko, 2% Increase in Ordinary Profit for The Current Fiscal Year
Maruto Sangyo, 15% Increase in Ordinary Profit for The Current Fiscal Year
VALUE CREATION, 50% Increase in Ordinary Profit, Record High for The First Time in Two Years, Dividend Raised by 0.5 yen
Daito Pharma, The Current Fiscal Year Ordinary Profit Revised Downward by 26%
KAWAKAMI PAINT, Dec-Feb (1Q) Ordinary Profit Turns to Loss
AFC-HD AMS Life Science, First Half Ordinary Profit Increases by 26%, Dec-Feb Ordinary Profit Increases by 10%